Hepatitis c virus and chronic kidney disease

References

• World Health Organization, Global Hepatitis Programme. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. [Internet]. 2018 [cited 2019 Nov 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK531733/
   Google Scholar
• Mohanty A, Salameh S, Butt AA. Impact of direct acting antiviral agent therapy upon extrahepatic manifestations of hepatitis C virus infection. Curr HIV/AIDS Rep. 2019;16(5):389–394.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Digestive Liver Dis. 2014;46:S165–S173.
   Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7(3):327–343.
   PubMed Web of Science ®Google Scholar
• Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. JASN. 2016;27(8):2238–2246.
   Web of Science ®Google Scholar
• Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73–86.
   PubMed Web of Science ®Google Scholar
• Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014;20(24):7544–7554.
   PubMed Web of Science ®Google Scholar
• Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol. 2008;49(4):613–624.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2018;8(3):91–165.
   Web of Science ®Google Scholar
• Fissell RB, Bragg-Gresham JL, Woods JD, et al., Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–2342.
   PubMed Web of Science ®Google Scholar
• Thompson ND, Novak RT, White-Comstock MB, et al. Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit. J Nephrol Therapeutic. 2012;S10:002.
   PubMedGoogle Scholar
• Sauné K, Kamar N, Miédougé M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26(7):2309–2316.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Bieber BA, Martin P, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;95(4):939–947.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38(9):471–480.
   PubMed Web of Science ®Google Scholar
• Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67(1):285–290.
   PubMed Web of Science ®Google Scholar
• Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57(3):396–402.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Buchanan P, Pinsky B, et al. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8(1):79–84.
   PubMed Web of Science ®Google Scholar
• Molnar MZ, Alhourani HM, Wall BM, et al. Association of Hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61(5):1495–1502.
   PubMed Web of Science ®Google Scholar
• Tsui JI. Association of Hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167(12):1271.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Lin H-Y, Li C-Y, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85(5):1200–1207.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Verdesca S, Messa P, et al., Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci. 2015;60(12):3801–3813.
   PubMed Web of Science ®Google Scholar
• Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22(11):897–905.
   PubMed Web of Science ®Google Scholar
• Li M, Wang P, Yang C, et al. A systematic review and meta-analysis: does hepatitis C virus infection predispose to the development of chronic kidney disease? Oncotarget. 2016;8(6):10692–10702.
   Google Scholar
• Peters L, Grint D, Lundgren JD, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26(15):1917–1926.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Neuhaus J, Peters L, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS ONE. 2012;7(7):e40245.
   PubMed Web of Science ®Google Scholar
• Noureddine LA, Usman SA, Yu Z, et al. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32(4):311–316.
   PubMed Web of Science ®Google Scholar
• Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28(9):2187–2191.
   PubMed Web of Science ®Google Scholar
• Hwang J, Jiang M, Lu Y, et al. Impact of HCV infection on diabetes patients for the risk of end-stage renal failure. Medicine (Baltimore). 2016;95(3):e2431.
   PubMed Web of Science ®Google Scholar
• Lee J, Lin M, Chang J, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS ONE. 2014;9(6):e100790.
   PubMed Web of Science ®Google Scholar
• Lai T-S, Lee M-H, Yang H-I, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study: lai et al. Hepatology. 2017;66(3):784–793.
   PubMed Web of Science ®Google Scholar
• Lai T-S, Lee M-H, Yang H-I, et al. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. Kidney Int. 2017;92(3):703–709.
   PubMed Web of Science ®Google Scholar
• Goodkin DA, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis c infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):287–297.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?: HCV and cardiovascular mortality in dialysis. J Viral Hepat. 2012;19(9):601–607.
   PubMed Web of Science ®Google Scholar
• Oyake N, Shimada T, Murakami Y, et al. Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol. 2008;21(3):345–353.
   PubMed Web of Science ®Google Scholar
• Lazo M, Nwankwo C, Daya NR, et al. Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the United States Population. Clin Gastroenterol Hepatol. 2017;15:1957–1964.e7.
   PubMed Web of Science ®Google Scholar
• Cruzado JM, Carrera M, Torras J, et al. Hepatitis C virus infection and de Novo Glomerular Lesions in renal allografts. Am J Transplant. 2001;1(2):171–178.
   PubMed Web of Science ®Google Scholar
• Scott DR, Wong JKW, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90(11):1165–1171.
   PubMed Web of Science ®Google Scholar
• Heo N-Y, Mannalithara A, Kim D, et al. Long-term patient and graft survival of kidney transplant recipients with Hepatitis C virus infection in the United States. Transplantation. 2018;102(3):454–460.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Dixit V, et al. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21(5):314–324.
   PubMed Web of Science ®Google Scholar
• Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22(6):1152–1160.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Messa P, Martin P, et al. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. Int J Artif Organs. 2008;31(8):675–682.
   PubMed Web of Science ®Google Scholar
• Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743–750.
   PubMed Web of Science ®Google Scholar
• Henson JB, Sise ME. The association of hepatitis C infection with the onset of CKD and progression into ESRD. Semin Dial. 2019;32(2):108–118.
   PubMed Web of Science ®Google Scholar
• Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010;59(8):1135–1140.
   PubMed Web of Science ®Google Scholar
• Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63(3):369–375.
   PubMed Web of Science ®Google Scholar
• Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345–1360.
   PubMed Web of Science ®Google Scholar
• Sciacqua A, Perticone M, Tassone EJ, et al. Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance. Intern Emerg Med. 2016;11(4):553–559.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496–502.
   PubMed Web of Science ®Google Scholar
• Francoz C, Glotz D, Moreau R, et al. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52(4):605–613.
   PubMed Web of Science ®Google Scholar
• Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–940.
   PubMed Web of Science ®Google Scholar
• Hsu Y-C, Lin J-T, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59(4):1293–1302.
   PubMed Web of Science ®Google Scholar
• Park H, Chen C, Wang W, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. Hepatology. 2018;67(2):492–504.
   PubMed Web of Science ®Google Scholar
• Hsu Y, Hung P, Muo C, et al. Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease. Medicine (Baltimore). 2015;94(47):e2113.
   PubMed Web of Science ®Google Scholar
• Söderholm J, Millbourn C, Büsch K, et al. Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis. J Hepatol. 2018;68(5):904–911.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Desbois AC, Comarmond C, et al. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025–2034.
   PubMed Web of Science ®Google Scholar
• Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–156.e2.
   PubMedGoogle Scholar
• Sise ME, Chute DF, Oppong Y, et al. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020;97(1):193–201.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326–334. quiz 504–505.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–853.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343–353.
   PubMed Web of Science ®Google Scholar
• Terrier B, Cacoub P. Renal involvement in HCV-related vasculitis. Clin Res Hepatol Gastroenterol. 2013;37(4):334–339.
   PubMed Web of Science ®Google Scholar
• Zignego A, Giannini C, Gragnani L. HCV and Lymphoproliferation. Clin Dev Immunol. 2012;2012:1–8.
   Google Scholar
• Sethi S, Fervenza FC. Membranoproliferative Glomerulonephritis — A New Look at an Old Entity. N Engl J Med. 2012;366(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25(5):1237–1244.
   PubMed Web of Science ®Google Scholar
• Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 2007;49(1):69–82.
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–374.
   PubMed Web of Science ®Google Scholar
• Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92(5):273–284.
   PubMed Web of Science ®Google Scholar
• Sabry A, E-Agroudy A, Sheashaa H, et al. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. Virology. 2005;334(1):10–16.
   PubMed Web of Science ®Google Scholar
• Stehman-Breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 1999;81(1):37–40.
   PubMed Web of Science ®Google Scholar
• Baid S, Pascual M, Williams WW, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10(1):146–153.
   PubMed Web of Science ®Google Scholar
• Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 1998;9(12):2244–2252.
   PubMed Web of Science ®Google Scholar
• Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA. 2005;102(51):18544–18549.
   PubMed Web of Science ®Google Scholar
• Kaplanski G, Maisonobe T, Marin V, et al. Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia. J Hepatol. 2005;42(3):334–340.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623–637.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Munshi N, Koziel MJ, et al. Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. J Gen Virol. 2005;86:3291–3301.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Desbois AC, Isnard-Bagnis C, et al. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65:S82–S94.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263–271.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials. Gastroenterology. 2017;153:113–122.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected], European association for the study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461–511.
   PubMed Web of Science ®Google Scholar
• Kanda T, Lau GKK, Wei L, et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13:103–109.
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67:1477–1492.
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Shaikh OS, et al. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016;36:651–658.
   PubMed Web of Science ®Google Scholar
• Brown RS, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72:441–449.
   PubMed Web of Science ®Google Scholar
• Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS. 2007;2:306–313.
   PubMed Web of Science ®Google Scholar
• Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816.
   PubMed Web of Science ®Google Scholar
• Eletreby R, El-Serafy M, Anees M, et al. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int. 2020;40:797–805.
   PubMed Web of Science ®Google Scholar
• Li M, Chen J, Fang Z, et al. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J. 2019;16(1):34. doi: 10.1186/s12985-019-1140-xi.
   Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.
   PubMed Web of Science ®Google Scholar
• Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–1455.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C Virus Genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590–1598.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Cohen E, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in patients with hepatitis C Virus genotype 1 or 4 infection and advanced kidney disease. Kidney Int Rep. 2018;4:257–266.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol. 2013;85:1019–1027.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–417.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–1482.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777–1782.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Garrido M, Pol S, et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152(20522062.e2). DOI:10.1053/j.gastro.2017.02.037.
   PubMedGoogle Scholar
• Obrișcă B, Jurubiță R, Sorohan B, et al. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review. Clin Rheumatol. 2019;38:3677–3687.
   PubMed Web of Science ®Google Scholar
• Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413–417.
   PubMed Web of Science ®Google Scholar
• Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55:2084–2085.
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Mariño Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology. 2018;155(311–315.e6). DOI:10.1053/j.gastro.2018.04.024.
   PubMedGoogle Scholar
• Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112:1298–1308.
   PubMed Web of Science ®Google Scholar
• Passerini M, Schiavini M, Magni CF, et al. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? Virological, immunological, and clinical data from a real-life experience. Eur J Gastroenterol Hepatol. 2018;30:1208–1215.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835–842.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Aghemo A, Lampertico P, et al. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Int J Artif Organs. 2018;41:306–318.
   PubMed Web of Science ®Google Scholar
• Butt AA, Ren Y, Puenpatom A, et al. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018;48:35–43.
   PubMed Web of Science ®Google Scholar
• Tsai M, Lin C, Hung C, et al. Evolution of renal function under direct‐acting antivirals treatment for chronic hepatitis C: A real‐world experience. J Viral Hepat. 2019;26:1404–1412.
   PubMed Web of Science ®Google Scholar
• Liu C-H, Lee M-H, Lin J-W, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020;72:839–846.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Hepatitis TA. C and renal transplantation in era of new antiviral agents. World J Transplant. 2018;8:84–96.
   PubMedGoogle Scholar
• Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588–1595.
   PubMed Web of Science ®Google Scholar
• Colombo M, Aghemo A, Liu H, et al. Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C Virus Genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109–117.
   PubMed Web of Science ®Google Scholar
• Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238–1246.
   PubMed Web of Science ®Google Scholar
• Gupta G, Kang L, Yu JW, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: analysis of United States national data. Clin Transplant. 2017;31(10):e13055.
   Web of Science ®Google Scholar
• Kadatz M, Klarenbach S, Gill J, et al. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am J Transplant. 2018;18:2457–2464.
   PubMed Web of Science ®Google Scholar
• Eckman MH, Woodle ES, Thakar CV, et al. Transplanting Hepatitis C virus-infected versus uninfected kidneys into hepatitis C virus-infected recipients: a cost-effectiveness analysis. Ann Intern Med. 2018;169:214–223.
   PubMed Web of Science ®Google Scholar
• Latt NL. Update on the management of hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. Gastroenterol Hepatol. 2018;14:687–705.
   Google Scholar
• Kiberd BA, Doucette K, Vinson AJ, et al. Hepatitis C virus-infected kidney waitlist patients: treat now or treat later? Am. J Transplant. 2018;18:2443–2450.
   Web of Science ®Google Scholar
• McCauley M, Mussell A, Goldberg D, et al. Race, risk, and willingness of end-stage renal disease patients without hepatitis C virus to accept an HCV-infected kidney transplant. Transplantation. 2018;102(4):e163.
   PubMed Web of Science ®Google Scholar
• Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273–281.
   PubMed Web of Science ®Google Scholar
• Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533–540.
   PubMed Web of Science ®Google Scholar
• Goel A, Bhadauria DS, Kaul A, et al. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology (Carlton). 2019;24(3):316–321.
   PubMed Web of Science ®Google Scholar
• Taneja S, Duseja A, De A, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63:1334–1340.
   PubMed Web of Science ®Google Scholar
• Liu C, Huang Y, Yang S, et al. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep. 2018;8(1):13699. DOI: 10.1038/s41598-018-32060-7.
   Web of Science ®Google Scholar
• Zeng Q-L, Xu G-H, Zhang J-Y, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. J Hepatol. 2017;66:1123–1129.
   PubMed Web of Science ®Google Scholar